APO-ONDANSETRON SOLUTION

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE)

Inapatikana kutoka:

APOTEX INC

ATC kanuni:

A04AA01

INN (Jina la Kimataifa):

ONDANSETRON

Kipimo:

4MG

Dawa fomu:

SOLUTION

Tungo:

ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) 4MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

15G/50G

Dawa ya aina:

Prescription

Eneo la matibabu:

5-HT3 RECEPTOR ANTAGONISTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0131120002; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2020-07-08

Tabia za bidhaa

_APO-ONDANSETRON (ondansetron hydrochloride dihydrate) _
_Page 1 of 37 _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
APO-ONDANSETRON
Ondansetron Oral Solution
Oral Solution, 4 mg /5 mL ondansetron (as ondansetron hydrochloride
dihydrate), Oral
USP
Antiemetic
5-HT
3
receptor antagonist
ATC Code A04AA01
Apotex Inc
150 Signet Drive
Toronto, Ontario
M9L 1T9
Date of Initial Authorization:
February 16, 2007
Date of Revision:
September 9, 2022
Submission Control Number: 261676
_APO-ONDANSETRON (ondansetron hydrochloride dihydrate) _
_Page 2 of 37 _
_ _
RECENT MAJOR LABEL CHANGES
1 INDICATIONS, Adults
09/2022
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and
Dosage Adjustment
09/2022
7 WARNINGS AND PRECAUTIONS, Cardiovascular, Myocardial
Ischemia and Coronary Artery Spasm
09/2022
7 WARNINGS AND PRECAUTIONS, Special Populations, 7.1.1
Pregnant Women
07/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES……………………………………………………………………………………………2
TABLE OF
CONTENTS……………………………………………………………………………………………………………..2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..................................................................................................................
4
1.1
Pediatrics (<18 years of age)
...........................................................................................
4
1.2
Geriatrics (>65 years of age)
...........................................................................................
4
2
CONTRAINDICATIONS
.....................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.....................................................................................
5
4.1
Dosing Considerations
........